|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.990 USD | -1.48% |
|
-4.47% | -32.09% |
| May. 07 | Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026 | |
| May. 06 | Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026 | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 33.15M | 6.28M | 2.51M | -18.9M | -220M | |||||
Depreciation & Amortization - CF | 1.36M | 1.22M | 920K | 859K | 4.91M | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 1.48M | 1.52M | 2.09M | 7.27M | 7.01M | |||||
Depreciation & Amortization, Total | 2.84M | 2.73M | 3.01M | 8.13M | 11.92M | |||||
(Gain) Loss on Sale of Investments - (CF) | 1.64M | -2.96M | -8.14M | -6.99M | -2.05M | |||||
Stock-Based Compensation (CF) | 15.37M | 16.28M | 14.04M | 12.43M | 9.47M | |||||
Other Operating Activities, Total | 8.47M | 3.59M | 2.13M | -3.87M | 83.39M | |||||
Change In Accounts Receivable | -2.47M | -1.09M | -707K | -13.01M | -7.46M | |||||
Change In Inventories | -2.23M | -4.48M | -771K | -29K | -3.47M | |||||
Change In Accounts Payable | 3.04M | 11.79M | -10.98M | 1.71M | 15.82M | |||||
Change in Other Net Operating Assets | 4.4M | -151K | 11.72M | 4.78M | 3.42M | |||||
Cash from Operations | 64.21M | 31.98M | 12.8M | -15.76M | -109M | |||||
Capital Expenditure | -552K | -679K | -101M | -4.72M | -998K | |||||
Sale (Purchase) of Intangible assets | - | - | - | - | - | |||||
Investment in Marketable and Equity Securities, Total | -76.14M | 50.6M | 88.99M | -12.71M | 95.86M | |||||
Other Investing Activities, Total | - | - | - | - | - | |||||
Cash from Investing | -76.7M | 49.92M | -12.06M | -17.43M | 94.86M | |||||
Long-Term Debt Repaid, Total | - | - | - | -155K | -1.99M | |||||
Total Debt Repaid | - | - | - | -155K | -1.99M | |||||
Issuance of Common Stock | 3.55M | 734K | - | - | - | |||||
Repurchase of Common Stock | - | - | - | - | -915K | |||||
Cash from Financing | 3.55M | 734K | - | -155K | -2.91M | |||||
Foreign Exchange Rate Adjustments | -91K | 265K | 47K | -163K | 23K | |||||
Net Change in Cash | -9.02M | 82.91M | 792K | -33.5M | -17.46M | |||||
Supplemental Items | ||||||||||
Cash Income Tax Paid (Refund) | - | - | 3.6M | 2.4M | -90K | |||||
Levered Free Cash Flow | 48.22M | 32.34M | -88.78M | -18.72M | -49.36M | |||||
Unlevered Free Cash Flow | 48.22M | 32.34M | -88.78M | -18.72M | -49.36M | |||||
Change In Net Working Capital | -4.21M | -10.06M | -3.94M | 9.15M | -24.73M | |||||
Net Debt Issued / Repaid | - | - | - | -155K | -1.99M |
Select your edition
All financial news and data tailored to specific country editions
















